The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept – the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission.

According to the CADTH website, Merck is seeking public reimbursement for 2 of the 5 approved indications for ENBREL™ in Canada: rheumatoid arthritis and ankylosing spondylitis.

This product marks the second major entrant in the Canadian SEB space (after Hospira’s Inflectra (infliximab)), and is the first significant SEB to be commercialized in Canada by a traditionally innovative pharmaceutical company.